Literature DB >> 25614211

Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in papillary thyroid carcinomas.

Xiang-xiang Zhan1, Bing Zhao, Chang Diao, Yi Cao, Ruo-chuan Cheng.   

Abstract

The incidence of thyroid cancer has appeared as an increasing trend globally, especially in Asian countries. In this study, the expression of mucin-1 (MUC1) and Thomsen-Friedenreich antigen, Galβ1-3GalNAcα1-R (CD176) was investigated by immunohistochemistry in papillary thyroid carcinomas (PTCs), which accounts for approximately 80 % of all thyroid cancer. We found that 78 % of PTC overexpressed MUC1. Importantly, we observed firstly that CD176 was expressed in 63 % of PTC, but was faintly or not expressed in normal thyroid tissues and benign thyroid disease tissues, indicating that CD176 is also a tumour-associated antigen for PTCs. Moreover, expression of CD176 was strongly correlated with MUC1 by immunohistochemical staining in PTCs. Furthermore, we used the immunochemical method to confirm that MUC1 is a common and main carrier of CD176 in PTCs. Our data demonstrated that MUC1 and CD176 might be promising biomarkers for thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25614211     DOI: 10.1007/s12022-015-9356-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  38 in total

1.  Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.

Authors:  Wei-Ming Lin; Uwe Karsten; Steffen Goletz; Ruo-Chuan Cheng; Yi Cao
Journal:  Int J Exp Pathol       Date:  2010-11-11       Impact factor: 1.925

2.  MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.

Authors:  I Bièche; E Ruffet; A Zweibaum; F Vildé; R Lidereau; B Franc
Journal:  Thyroid       Date:  1997-10       Impact factor: 6.568

3.  Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.

Authors:  Pamela L Beatty; Olivera J Finn
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

5.  Immunotherapy: Chemical tricks.

Authors:  Bianca Nogrady
Journal:  Nature       Date:  2014-09-11       Impact factor: 49.962

6.  Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions.

Authors:  Y Cao; U Karsten; G Otto; P Bannasch
Journal:  Virchows Arch       Date:  1999-06       Impact factor: 4.064

7.  Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation.

Authors:  Y Cao; U R Karsten; W Liebrich; W Haensch; G F Springer; P M Schlag
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

8.  CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia.

Authors:  Bin Yi; Zhe Zhang; Min Zhang; Reinhard Schwartz-Albiez; Yi Cao
Journal:  Oncol Rep       Date:  2013-07-25       Impact factor: 3.906

9.  Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995.

Authors:  T Haselkorn; L Bernstein; S Preston-Martin; W Cozen; W J Mack
Journal:  Cancer Causes Control       Date:  2000-02       Impact factor: 2.506

Review 10.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

View more
  2 in total

1.  The Potential Action of Thomsen-Friedenreich Monoclonal Antibody (A78-G/A7) in Thyroid Cancer.

Authors:  Ying Peng; Xiang-Xiang Zhan; Yi Cao; Han-Wen Zhang; Wei-Han Cao; Yan-Jun Su; Chang Diao; Qiang-Ming Sun; Ruo-Chuan Cheng
Journal:  Onco Targets Ther       Date:  2020-08-25       Impact factor: 4.147

2.  BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.

Authors:  Cong Zhang; Chunrui Bo; Lunhua Guo; Pingyang Yu; Susheng Miao; Xin Gu
Journal:  World J Surg Oncol       Date:  2019-12-16       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.